01942nas a2200229   4500008004100000022001400041245008000055210006900135260000800204490000700212520122900219653001501448653001301463653001801476653001501494653003201509100001801541700001901559700001901578700001901597856009601616       2021                        eng d  a2190-572X00aProbiotics in the prophylaxis of COVID-19: something is better than nothing0 aProbiotics in the prophylaxis of COVID19 something is better tha  cJAN0 v113 a<p>The new viral pandemic of COVID-19 is caused by a novel coronavirus (SARS-CoV-2) that has brought the world at another unprecedented crisis in terms of health and economy. The lack of specific therapeutics necessitates other strategies to prevent the spread of infection caused by this previously unknown viral etiological agent. Recent pieces of evidence have shown an association between COVID-19 disease and intestinal dysbiosis. Probiotics comprise living microbes that upon oral administration benefit human health by reshaping the composition of gut microbiota. The close kinship of the gastrointestinal and respiratory tract suggests why the dysfunction of one may incite illness in others. The emerging studies suggest the capability of probiotics to regulate immune responses in the respiratory system. The efficacy of probiotics has been studied previously on several respiratory tract viral infections. Therefore, the purpose of this review is to comprehend existing information on the gut mediated-pulmonary immunity conferred by probiotic bacteria, in the course of respiratory virus infections and administration as a prophylactic measure in COVID-19 pandemic in managing intestinal dysbiosis as well.</p>
10aAnti-viral10aCOVID-1910aGut-lung axis10aProbiotics10aRespiratory tract infection1 aGohil, Kushal1 aSamson, Rachel1 aDastager, Syed1 aDharne, Mahesh  uhttps://library.ncl.res.in/content/probiotics-prophylaxis-covid-19-something-better-nothing01919nas a2200217   4500008004100000022001400041245009000055210006900145260000800214300000600222490000700228520123200235653001501467653001301482653001601495653001701511653001501528100001901543700001901562856012001581       2022                        eng d  a2190-572X00aCOVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis0 aCOVID19 associated mucormycosis evolving technologies for early   cJAN  a60 v123 aThe post-coronavirus disease (COVID-19) mucormycosis is a deadly addition to the pandemic spectrum. Although it's a rare, aggressive, and opportunistic disease, the associated morbidity and mortality are significant. The complex interplay of factors aggravating CAM is uncontrolled diabetes, irrational and excessive use of antibiotics, steroids, and an impaired immune system. Recently, India has been witnessing a rapid surge in the cases of coronavirus disease-associated mucormycosis (CAM), since the second wave of COVID-19. The devastating and lethal implications of CAM had now become a matter of global attention. A delayed diagnosis is often associated with a poor prognosis. Therefore, the rapid and early diagnosis of infection would be life-saving. Prevention and effective management of mucormycosis depend upon its early and accurate diagnosis followed by a multimodal therapeutic approach. The current review summarizes an array of detection methods and highlights certain evolving technologies for early and rapid diagnosis of CAM. Furthermore, several potential management strategies have also been discussed, which would aid in tackling the neglected yet fatal crisis of mucormycosis associated with COVID-19.10aBiosensors10aCOVID-1910aDiagnostics10aMucormycosis10aProbiotics1 aSamson, Rachel1 aDharne, Mahesh  uhttps://library.ncl.res.in/content/covid-19-associated-mucormycosis-evolving-technologies-early-and-rapid-diagnosis